ReviewThe Lancet. Global health2022
Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis.
Review in The Lancet. Global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07259616 (Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities), which is not on this map. Cited by 332 papers, 13 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities
Who cites it
332 citing papers in PubMed, 13 syntheses or guidelines pooled it, 484 citations in OpenAlex.
- Cervical cancer screening policy inequality worldwide: a systematic review of disparities in access and implementation.Journal of translational medicine · 2026Pooled it
- Cultural and traditional influences on cervical cancer screening uptake in Nigeria and other West African countries.BMC public health · 2026Pooled it
- Estimates of the global burden of HIV-attributable and all-cause AIDS-defining cancers: a population-based modeling study.Frontiers in public health · 2026Pooled it
- Prevalence of Cervical Cancer Screening in Asia: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Prevalence of oral human papillomavirus infection in African countries: a systematic review and meta-analysis.Pathogens and global health · 2025Pooled it
- Uptake of cervical cancer screening and its associated factors in Africa: an umbrella review of systematic reviews and meta-analyses.BMC public health · 2025Pooled it
- Cervical cancer screening uptake in East Africa: a systematic review and meta-analysis of observational studies.BMC public health · 2025Pooled it
- Utilization of cervical cancer screening and its associated factors among women living with HIV in East Africa: a systematic review and meta-analysis.BMC women's health · 2025Pooled it
- Worldwide burden of cervical human papillomavirus (HPV) in women over 50 years with abnormal cytology: a systematic review and meta-analysis.BMJ global health · 2025Pooled it
- Association of female genital schistosomiasis and human papillomavirus and cervical pre-cancer: a systematic review.BMC women's health · 2025Pooled it
- Pooled it
- Developing and validating key performance indicators for breast, cervical, and colorectal cancer screening programs: a literature review and Delphi survey.Frontiers in public health · 2025Pooled it
- Cancer and Syria in conflict: a systematic review.BMC cancer · 2024Pooled it
- Comparison of three different hpv self-sampling tools - a subanalysis of the prospective, randomized hannover self-collection study.Archives of gynecology and obstetrics · 2026Trial
- Variations in the Natural History of High-Risk HPV Types Following HPV-16/18 Bivalent Vaccination in Females Aged 18-45 Years.Nature communications · 2026Trial
- HPV genotyping agreement between paired cervical cytological sample and biopsy across lesion severity and vaccination.Virology journal · 2025Trial
- Participation and relative cost of attendance by direct-mail compared to opt-in invitation strategy for HPV self-sampling targeting cervical screening non-attenders: A large-scale, randomized, pragmatic study.International journal of cancer · 2025Trial
- Assessing the burden of HPV-associated cancers in Brazil: Hospitalization and mortality trends from 2011 to 2019.Human vaccines & immunotherapeutics · 2026Article
- Implementation of self-collected cervical screening in an under-screened, culturally and linguistically diverse antenatal population: a quality improvement study.BMJ open quality · 2026Article
- Long-Term Regional Pathology-Detection Trends in High-Grade Cervical Lesions and Cervical Squamous Cell Carcinoma Among Women Aged 40-69 Years in Northern Norway, 1998-2025.Diagnostics (Basel, Switzerland) · 2026Article
272 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 7 institutions in 7 countries.
Funding
Abstract
backgroundCervical cancer screening coverage is a key monitoring indicator of the WHO cervical cancer elimination plan. We present global, regional, and national cervical screening coverage estimates against the backdrop of the 70% coverage target set by WHO.
methodsIn this review and synthetic analysis, we searched scientific literature, government websites, and official documentation to identify official national recommendations and coverage data for cervical cancer screening for the 194 WHO member states and eight associated countries and territories published from database inception until Oct 30, 2020, supplemented with a formal WHO country consultation from Nov 27, 2020, to Feb 12, 2021. We extracted data on the year of introduction of recommendations, the existence of individual invitation to participate, financing of screening tests, primary screening and triage tests used, recommended ages and screening intervals, use of self-sampling, and use of screen-and-treat approaches. We also collected coverage data, either administrative or survey-based, as disaggregated as possible by age and for any available screening interval. According to data completeness and representativeness, different statistical models were developed to produce national age-specific coverages by screening interval, which were transformed into single-age datapoints. Missing data were imputed. Estimates were applied to the 2019 population and aggregated by region and income level.
findingsWe identified recommendations for cervical screening in 139 (69%) of 202 countries and territories. Cytology was the primary screening test in 109 (78%) of 139 countries. 48 (35%) of 139 countries recommended primary HPV-based screening. Visual inspection with acetic acid was the most recommended test in resource-limited settings. Estimated worldwide coverage in women aged 30-49 years in 2019 was 15% in the previous year, 28% in the previous 3 years, and 32% in the previous 5 years, and 36% ever in lifetime. An estimated 1·6 billion (67%) of 2·3 billion women aged 20-70 years, including 662 million (64%) of 1·0 billion women aged 30-49 years, had never been screened for cervical cancer. 133 million (84%) of 158 million women aged 30-49 years living in high-income countries had been screened ever in lifetime, compared with 194 million (48%) of 404 million women in upper-middle-income countries, 34 million (9%) of 397 million women in lower-middle-income countries, and 8 million (11%) of 74 million in low-income countries.
interpretationTwo in three women aged 30-49 years have never been screened for cervical cancer. Roll-out of screening is very low in low-income and middle-income countries, where the burden of disease is highest. The priority of the WHO elimination campaign should be to increase both screening coverage and treatment of detected lesions; however, expanding the efforts of surveillance systems in both coverage and quality control are major challenges to achieving the WHO elimination target.
fundingInstituto de Salud Carlos III, European Regional Development Fund, Secretariat for Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and Horizon 2020. TRANSLATIONS: For the French, Spanish translations of the abstract see Supplementary Materials section.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.